Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · IEX Real-Time Price · USD
13.14
-1.36 (-9.38%)
May 10, 2024, 4:30 PM EDT - Market closed
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
58
Market Cap
432.93M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
| Dec 31, 2021 | 1.66M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLXEO News
- 3 days ago - Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 5 days ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 20 days ago - Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - GlobeNewsWire
- 26 days ago - Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing - GlobeNewsWire
- 3 months ago - Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments - GlobeNewsWire